Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

In a study of Eli Lilly’s Zepbound, weight loss increased (PDF) from 20.9% after 36 weeks to 25.8% after 88 weeks. The top-line data shared by Novo Friday lack important details, including ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Unlike many other online weight ... after 12 months than those who took semaglutide. A 2024 study suggests you may get better weight loss results with tirzepatide, the active ingredient in ...

Many people on these weight-loss drugs - which include Ozempic, Wegovy, Zepbound and Mounjaro - report that they're shelling out more for clothes and a variety of other goods and services to fit ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro. After months of high demand and supply constraints, this news marks a significant ...